v3.26.1
Asset Acquisition - Summary of Fair Value of the Consideration Transferred to the Net Assets Acquired and Liabilities Assumed with the Excess Recorded to Loss on Acquisition (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
May 18, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Liabilities assumed:          
Gain on Orphai Acquisition   $ (1,305) $ 0 $ (1,305) $ 0
Orphai Therapeutics [Member]          
Assets acquired:          
Cash and cash equivalents $ 8,001        
Prepaid expenses and other current expenses 451        
In-process research and development [1] 59,000        
Total assets acquired 67,452        
Liabilities assumed:          
Trade payables (3,097)        
Accrued expenses and other current liabilities (6,186)        
Total liabilities assumed (9,283)        
Fair value of assets acquired and liabilities assumed 58,169        
Gain on Orphai Acquisition $ (1,305)        
[1] IPR&D represents the research and development projects of Orphai which were in-process, but not yet completed, and which the Company plans to advance. The fair value of IPR&D projects acquired in an asset acquisition with no alternative future use are allocated a portion of the consideration transferred and charged to expenses at the acquisition date.